Key result
Aspirin half maximal inhibitory concentration values on platelet cyclooxygenase activity did not differ significantly between patients with severe type-2 diabetes and healthy individuals.
Why the study?
Does aspirin have different inhibitory effects on platelet cyclooxygenase activity in patients with severe type-2 diabetes mellitus compared to healthy individuals?
Case-Control
Does aspirin have different inhibitory effects on platelet cyclooxygenase activity in patients with severe type-2 diabetes mellitus compared to healthy individuals?
Aspirin's inhibitory effect on platelet cyclooxygenase activity is not significantly different in severe type-2 diabetes patients compared to healthy individuals, suggesting residual aggregability is independent of COX activity and may be driven by ADP hyperreactivity.
Answers are grounded in this paper and cite their sources.
Similar aspirin platelet effects in severe T2DM versus controls do not support practice changes; hypothesis-generating for larger trials.
It is implicated that diabetic patients are more resistant to aspirin therapy than patients with other diseases or healthy individuals. We evaluated the inhibitory effects of aspirin on aggregation and the cyclooxygenase activity of platelets of 10 patients with severe type-2 diabetes mellitis (DM) and compared the results with those of healthy individuals. Although platelet aggregation had a tendency to be more resistant to aspirin with the DM group, there was no significant difference in half maximal inhibitory concentration 50 values of aspirin on the cyclooxygenase activity between the patients with DM and healthy individuals. Thus, the residual platelet aggregability uninhibited by aspirin appears to be independent of the cyclooxygenase activity. Since adenosine diphosphate (ADP) receptor blocking almost completely inhibited the residual platelet aggregability, it is suggested that hyperreactivity to ADP is more prevalent in patients with DM.
No takes yet. Share an insight, caveat, or question.
Kimura et al. (2013) conducted a case-control in Severe type-2 diabetes mellitus. Aspirin vs. Healthy individuals was evaluated on Half maximal inhibitory concentration (IC50) of aspirin on cyclooxygenase activity. Aspirin half maximal inhibitory concentration values on platelet cyclooxygenase activity did not differ significantly between patients with severe type-2 diabetes and healthy individuals.
Synapse has enriched 10 related papers. Consider them for comparative context: